X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration, used to treat multiple myeloma and mantle cell lymphoma.
Lead Product(s): Bortezomib
Therapeutic Area: Oncology Product Name: Bortezomib-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2022
Details:
Sarclisa (isatuximab) is a CD38 monoclonal antibody in combination with standard-of-care bortezomib, lenalidomide and dexamethasone is being evaluated in newly diagnosed multiple myeloma not eligible for transplant.
Lead Product(s): Isatuximab,Lenalidomide,Bortezomib
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Iran Expo
Not Confirmed
Contact SupplierDetails:
Blenrep (belantamab mafodotin-blmf) is a humanized anti-BCMA antibody/drug conjugate. It is being evaluated in phase 3 clinical trials in combination with pomalidomide, bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Blenrep
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
Johnson-approved product Darzalex (daratumumab), which is a CD38 inhibitor, currently it is being evaluated in Phase III clinical trials in combination with bortezomib, lenalidomide, dexamethasone for the treatment of multiple myeloma.
Lead Product(s): Daratumumab,Bortezomib,Lenalidomide
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
Blenrep (belantamab mafodotin-blmf) is a humanized anti-BCMA antibody/drug conjugate. It is being evaluated in phase 3 clinical trials in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Blenrep
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
STAR-LLD is a continuous delivery lenalidomide (LLD), which is under phase 1 clinical development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
Darzalex Faspro (daratumumab) is a CD38 inhibitor antibody drug candidate, which is currently being evaluated in combination with hyaluronidase & bortezomib for the treatment of patients with newly diagnosed multiple myeloma.
Lead Product(s): Daratumumab,Hyaluronidase,Bortezomib
Therapeutic Area: Oncology Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
Blenrep (belantamab mafodotin) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate. It is being evaluated for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Blenrep
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
STAR-LLD is a continuous delivery lenalidomide in development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: STAR-LDD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
The Company remains focused and committed to the completion of its Phase 1b STAR-LLD clinical trial in multiple myeloma study in order to bring patients a potentially superior delivery of continuous subcutaneous administration of lenalidomide.
Lead Product(s): Lenalidomide,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: STAR-LDD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Healthwell Acquisition Corp. I
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination November 03, 2023
Details:
Bortezomib intravenous injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and adult patients with mantle cell lymphoma.
Lead Product(s): Bortezomib
Therapeutic Area: Oncology Product Name: Bortezomib-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export inhibitor approved by the Therapeutic Goods Administration of Australia for patients with relapsed and/or refractory multiple myeloma and in triple class refractory R/R MM.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
Nexpovio (selinexor) reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Birtamimab, formerly known as NEOD001, is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.
Lead Product(s): Birtamimab,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 13, 2022
Details:
Birtamimab is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.
Lead Product(s): Birtamimab,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
XPOVIO (selinexor) is an oral medicine used to treat adults with multiple myeloma or relapsed/refractory diffuse large B-cell lymphoma. Antengene has successfully transitioned to an innovative company with a pipeline of 15 novel, clinical and preclinical programs for oncology.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
In primary analysis, GRIFFIN study met primary endpoint, resulting in higher stringent complete response rate for DARZALEX®-RVd (daratumumab) compared with RVd alone by end of post-autologous stem cell transplant consolidation therapy meeting prespecified 1-sided alpha of 0.1.
Lead Product(s): Daratumumab,Lenalidomide,Bortezomib
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2022
Details:
Nexpovio (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor, in combination with once weekly bortezomib and low-dose dexamethasone for treatment of adults with multiple myeloma who have received one to three prior lines of therapy.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Selinexor is the first and only oral XPO1 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
Xpovio (selinexor) is the first and only oral XPO1 inhibitor approved by U.S. Food and Drug Administration (FDA) for treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2022
Details:
Bortezomib-Generic is therapeutically equivalent to Takeda Pharmaceuticals' Velcade for Injection, is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.
Lead Product(s): Bortezomib
Therapeutic Area: Oncology Product Name: Bortezomib-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
Bortezomib, a new generic equivalent to Velcade® in U.S, is available in a 3.5 mg per 10mL single-dose vial presentation for subcutaneous or intravenous use, a treatment option for adult patients with multiple myeloma and mantle cell lymphoma.
Lead Product(s): Bortezomib
Therapeutic Area: Oncology Product Name: Bortezomib-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
XPOVIO® is first new class SINE medicine, in combination with bortezomib and dexamethasone (XBd), for treatment of patients with multiple myeloma, and in combination with dexamethasone (Xd), gives patients with triple class refractory multiple myeloma, a new treatment option.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
Proceeds will be used to develop and commercialize company's lead product candidate, ciltacabtagene autoleucel (cilta-cel), an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma.
Lead Product(s): Ciltacabtagene Autoleucel,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Cilta-cel
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 14, 2021
Details:
Caelum was acquired by AstraZeneca pursuant to the developing and commercializing biopharmaceutical products and product candidates cost-effectively including Caelum’s lead asset, CAEL-101, is a novel antibody for the treatment of patients with light chain (“AL”) amyloidosis.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $350.0 million Upfront Cash: $150.0 million
Deal Type: Acquisition October 06, 2021
Details:
AstraZeneca will accelerate ongoing Phase III clinical development of CAEL-101, a potential first-in-class medicine which is being evaluated in the Cardiac Amyloid Reaching for Extended Survival Phase III clinical programme in combination with standard-of-care therapy.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition September 29, 2021
Details:
Selinexor is also being evaluated in several other mid-and later-phase clinical trials across multiple solid tumor indications, including liposarcoma and endometrial cancer.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2021
Details:
Approval of daratumumab SC-based regimen in Light Chain (AL) amyloidosis is supported by the Phase 3 ANDROMEDA study, which demonstrated significantly higher haematologic complete response rate vs. commonly used standard-of-care regimen.
Lead Product(s): Daratumumab,Hyaluronidase,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
An e-poster featuring the first data from a new arm of the study demonstrated that CAEL-101 administered in combination with cyclophosphamide-bortezomib-dexamethasone (CyBorD) plus daratumumab was generally safe and well-tolerated in the first four weeks of treatment.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
DARZALEX FASPRO® is the only CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma and now AL amyloidosis.
Lead Product(s): Daratumumab,Hyaluronidase,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
Details:
The Positive CHMP Opinion for daratumumab SC in combination with Pd in the treatment of MM is supported by data from the Phase 3 APOLLO study conducted in collaboration with the European Myeloma Network.
Lead Product(s): Daratumumab,Bortezomib,Cyclophosphamide
Therapeutic Area: Genetic Disease Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
DARZALEX® SC combination regimen is supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder.
Lead Product(s): Daratumumab,Bortezomib,Cyclophosphamide
Therapeutic Area: Genetic Disease Product Name: Darzalex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
Accelerated approval of DARZALEX FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder.
Lead Product(s): Daratumumab,Hyaluronidase-fihj,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Darzalex Faspro
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
XPOVIO® is a first-in-class and only-in-class oral SINE compound, and now the first and only drug approved by FDA for use in both multiple myeloma and diffuse large B-cell lymphoma, discovered and developed by Karyopharm, is currently being developed by Antengene.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
Phase 2 GRIFFIN data presented at ASH 2020 show increased stringent complete response and minimal residual disease negativity rates with maintenance therapy for transplant-eligible patients.
Lead Product(s): Daratumumab,Lenalidomide,Bortezomib
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Triplet regimen with melflufen plus dexamethasone in combination with daratumumab or bortezomib in heavily pretreated patients with relapsed refractory multiple myeloma had a similar safety profile compared to doublet regimen with only melflufen plus dexamethasone.
Lead Product(s): Melphalan Flufenamide,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: Melflufen
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2020
Details:
XPOVIO® (selinexor, ATG-010) is a first-in-class and only-in-class oral selective inhibitor of nuclear export, developed by Antengene and Karyopharm Therapeutics Inc.
Lead Product(s): Selinexor,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: XPOVIO
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
Once-weekly regimen of XPOVIO and Velcade®, with low-dose dexamethasone (SVd) reduced the risk of disease progression or death by 30% and induced a higher rate of overall and deep responses compared to patients receiving a standard twice-weekly Velcade®.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis. Data, from Caelum, that further shows safety and tolerability of CAEL-101 and support the selection of the 1000 mg/m2 dose for the Phase 3 study will also be presented.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Phase 2 data on Caelum Biosciences’ (“Caelum”) CAEL-101 for the treatment of relapsed or refractory amyloid light chain “AL” amyloidosis will be presented by the Cleveland Clinic during oral and poster sessions.
Lead Product(s): CAEL-101,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: CAEL-101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alexion Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
DARZALEX® SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX® (daratumumab).
Lead Product(s): Daratumumab,Bortezomib,Melphalan
Therapeutic Area: Oncology Product Name: Darzalex SC
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
FDA has accepted for filing its supplemental New Drug Application seeking approval for XPOVIO® (selinexor), its first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for multiple myeloma after at least one prior line of therapy.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Combination of once-weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) and Dexamethasone (svd) prolonged median progression-free survival by 47% compared to standard twice-weekly velcade® plus dexamethasone (Vd).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
13-month update on the DREAMM-2 study shows median overall survival of 14.9 months and median duration of response of 11 months with single-agent belantamab mafodotin 2.5 mg/kg dose.
Lead Product(s): Belantamab mafodotin,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
sNDA is backed by the top-line results from the pivotal Phase 3 BOSTON study evaluating the combination of XPOVIO (selinexor), once-weekly Velcade® (bortezomib) and low-dose dexamethasone as a second line treatment for patients with relapsed or refractory multiple myeloma.
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
